TRIB

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues update on Nasdaq listing DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting continued commercial progress, operational transformation and diagnostic pipeline advancement. Strengthening Commercial Leadership in Europe Trinity Biotech is pleased to announce that Jordi Romero has joined the Company as Head of Commercial Operations – Europe.

-  Collaboration with leading hyperscale data center company will support Trinovium's technical and commercial readiness through development of cooling technologies for next-generation AI and modular data center infrastructure - Data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and WILSONVILLE, Ore., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ: TRIB) today announced that Trinovium, a subsidiary focused on advanced liquid cooling solutions and fluid intelligence systems for next-generation AI data centers, has agreed to enter into a strategic collaboration agreement with Echelon Data Centres (“Echelon”), a leading hyperscale data center owner, developer and operator, to develop next-generation high-performance liquid cooling solutions for AI and high-density computing environments.

– Perceptive Advisors provides approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company's business transformation – – Trinity Biotech regains compliance with Nasdaq's minimum bid price requirement – DUBLIN, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced it secured additional investment from funds managed by Perceptive Advisors, a leading life sciences investment firm and Trinity Biotech's largest financial investor and primary lender. The Company also announced that it has regained compliance with Nasdaq's minimum bid price requirement, marking another positive development as Trinity Biotech continues to execute its strategic priorities.

- Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop next-generation metabolic health solutions -

DUBLIN, July 22, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing twenty (20) Class A ordinary shares to one (1) ADS representing six hundred (600) Class A ordinary shares.

- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+  's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose-only CGM monitoring - Reinforces differentiation opportunity for CGM+ within the $15 billion1 global CGM market DUBLIN and WILSONVILLE, Ore., July 02, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced clinical study results demonstrating that its next-generation CGM+ wearable biosensor platform has successfully delivered a purpose-built capability to identify nocturnal compression-related false low glucose events, with its differentiated technology addressing a common limitation of conventional continuous glucose monitoring (CGM) systems.

- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and WILSONVILLE, Ore., June 30, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that Trinovium, its recently established subsidiary focused on high-performance liquid cooling solutions for AI data centers, has secured Silver Membership in the Open Compute Project (OCP), providing Trinovium with a platform to directly engage with one of the most influential global ecosystems shaping next-generation data center infrastructure.

DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.

- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance computing environments

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets